Multiple Myeloma

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Drs Haumschild, Anderson, and Hinojosa provide their closing thoughts regarding treatment considerations for patients with RRMM.

Navigating treatment toxicities is paramount to achieving treatment goals in MM management.

The medical experts discuss strategies to achieve treatment adherence.

Social determinants of health inhibit optimal impact of MM treatment.

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Experts discuss the role of proteasome inhibitors in combination therapy in the management of relapsed indolent multiple myeloma.

Experts navigate the impact of proteasome inhibitors and anti-CD38 antibody therapies in the relapsed refractory multiple myeloma treatment landscape.

Experts highlight the use of 3- and 4-drug regimens for managing relapsed refractory multiple myeloma.

Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.

Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.

Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.

Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.